普通外文研报
Siemens Healthineers AG: Feedback from the European Leadership conference
研报英文原文证据摘录
Siemens Healthineers AG: Feedback from the European Leadership conference
Equity Research
European Medical Technology & Services
22 May 2026
Siemens Healthineers AG
Feedback from the European
Leadership conference
Service contracts a good inflation hedge given CPI clauses. SHLG.DE/SHL GY OVERWEIGHT
POSITIVEPricing measures set out at CMD now easier to achieve. Work EuropeanTechnologyMedical& Services
ongoing on carving out Diagnostics. Reimbursement changes Price Target EUR 50.00
in RT not seen as a major topic. Limited visibility on 232 but Price (21-May-26) EUR 34.51 Potential Upside/Downside +44.9%
Source: Bloomberg, Barclays Researchcould be “tailor-made” and exclude PCCT.
We were pleased to host Marc Koebernick, Siemens Healthineers' Head of Investor Relations, at European Medical Technology &
our European Leadership conference yesterday. We highlight our three key takeaways below. Services
Hassan Al-Wakeel, CFA
1.1. Inflation: The company believes they are well equipped in deal with inflation with service +44 (0)20 7773 3898
contracts having CPI clauses and thus providing a good hedge. Price increases in MR come hassan.al-wakeel@barclays.com
Barclays, UK at a 6-12 month lag given lead times, although this is trending down since helium free
requires less preparation time, whilst radiotherapy has longer lead times. They also believe Jonathon Unwin
that their pricing ambitions set out at CMD of 1% between CMD and 2028 would be easier to +44 (0)20 7773 0354
realise given higher inflation. jonathon.unwin@barclays.com
Barclays, UK
2.2. Radiation Therapy reimbursement: Reimbursement risks is not seen as a major topic or Marco Pires-Cox
discussed internally. Varian has 80% market share in the US and has seen no impact on +44 (0)20 3134 3421
order growth.
本摘录由系统从所标注的 PDF 证据页直接提取并保留英文原文,不做批量翻译;登录后在阅读器切换中文时才按需翻译。
打开研报阅读器